Copyright Reports & Markets. All rights reserved.

Global Basal Cell Carcinoma Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Basal Cell Carcinoma Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Basal Cell Carcinoma Treatment Market Size Growth Rate by Product
      • 1.4.2 Surgical Excision
      • 1.4.3 Electrodessication & Cutterage
      • 1.4.4 Moh's Surgery
      • 1.4.5 Cryosurgery
    • 1.5 Market by End User
      • 1.5.1 Global Basal Cell Carcinoma Treatment Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Specialty Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Basal Cell Carcinoma Treatment Market Size
      • 2.1.1 Global Basal Cell Carcinoma Treatment Revenue 2014-2025
      • 2.1.2 Global Basal Cell Carcinoma Treatment Sales 2014-2025
    • 2.2 Basal Cell Carcinoma Treatment Growth Rate by Regions
      • 2.2.1 Global Basal Cell Carcinoma Treatment Sales by Regions
      • 2.2.2 Global Basal Cell Carcinoma Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Basal Cell Carcinoma Treatment Sales by Manufacturers
      • 3.1.1 Basal Cell Carcinoma Treatment Sales by Manufacturers
      • 3.1.2 Basal Cell Carcinoma Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Basal Cell Carcinoma Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Basal Cell Carcinoma Treatment Revenue by Manufacturers
      • 3.2.1 Basal Cell Carcinoma Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Basal Cell Carcinoma Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Basal Cell Carcinoma Treatment Price by Manufacturers
    • 3.4 Basal Cell Carcinoma Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Basal Cell Carcinoma Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Basal Cell Carcinoma Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Basal Cell Carcinoma Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Basal Cell Carcinoma Treatment Sales by Product
    • 4.2 Global Basal Cell Carcinoma Treatment Revenue by Product
    • 4.3 Basal Cell Carcinoma Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Basal Cell Carcinoma Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Basal Cell Carcinoma Treatment by Countries
      • 6.1.1 North America Basal Cell Carcinoma Treatment Sales by Countries
      • 6.1.2 North America Basal Cell Carcinoma Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Basal Cell Carcinoma Treatment by Product
    • 6.3 North America Basal Cell Carcinoma Treatment by End User

    7 Europe

    • 7.1 Europe Basal Cell Carcinoma Treatment by Countries
      • 7.1.1 Europe Basal Cell Carcinoma Treatment Sales by Countries
      • 7.1.2 Europe Basal Cell Carcinoma Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Basal Cell Carcinoma Treatment by Product
    • 7.3 Europe Basal Cell Carcinoma Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Basal Cell Carcinoma Treatment by Countries
      • 8.1.1 Asia Pacific Basal Cell Carcinoma Treatment Sales by Countries
      • 8.1.2 Asia Pacific Basal Cell Carcinoma Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Basal Cell Carcinoma Treatment by Product
    • 8.3 Asia Pacific Basal Cell Carcinoma Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Basal Cell Carcinoma Treatment by Countries
      • 9.1.1 Central & South America Basal Cell Carcinoma Treatment Sales by Countries
      • 9.1.2 Central & South America Basal Cell Carcinoma Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Basal Cell Carcinoma Treatment by Product
    • 9.3 Central & South America Basal Cell Carcinoma Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Basal Cell Carcinoma Treatment by Countries
      • 10.1.1 Middle East and Africa Basal Cell Carcinoma Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Basal Cell Carcinoma Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Basal Cell Carcinoma Treatment by Product
    • 10.3 Middle East and Africa Basal Cell Carcinoma Treatment by End User

    11 Company Profiles

    • 11.1 Sun Pharmaceuticals
      • 11.1.1 Sun Pharmaceuticals Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Sun Pharmaceuticals Basal Cell Carcinoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Sun Pharmaceuticals Basal Cell Carcinoma Treatment Products Offered
      • 11.1.5 Sun Pharmaceuticals Recent Development
    • 11.2 Valeant Pharmaceuticals International
      • 11.2.1 Valeant Pharmaceuticals International Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Valeant Pharmaceuticals International Basal Cell Carcinoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Valeant Pharmaceuticals International Basal Cell Carcinoma Treatment Products Offered
      • 11.2.5 Valeant Pharmaceuticals International Recent Development
    • 11.3 Mylan N.V.
      • 11.3.1 Mylan N.V. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Mylan N.V. Basal Cell Carcinoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Mylan N.V. Basal Cell Carcinoma Treatment Products Offered
      • 11.3.5 Mylan N.V. Recent Development
    • 11.4 F. Hoffmann-La Roche Ltd
      • 11.4.1 F. Hoffmann-La Roche Ltd Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 F. Hoffmann-La Roche Ltd Basal Cell Carcinoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 F. Hoffmann-La Roche Ltd Basal Cell Carcinoma Treatment Products Offered
      • 11.4.5 F. Hoffmann-La Roche Ltd Recent Development
    • 11.5 Merck & Co.
      • 11.5.1 Merck & Co. Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Merck & Co. Basal Cell Carcinoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Merck & Co. Basal Cell Carcinoma Treatment Products Offered
      • 11.5.5 Merck & Co. Recent Development

    12 Future Forecast

    • 12.1 Basal Cell Carcinoma Treatment Market Forecast by Regions
      • 12.1.1 Global Basal Cell Carcinoma Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Basal Cell Carcinoma Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Basal Cell Carcinoma Treatment Market Forecast by Product
      • 12.2.1 Global Basal Cell Carcinoma Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Basal Cell Carcinoma Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Basal Cell Carcinoma Treatment Market Forecast by End User
    • 12.4 North America Basal Cell Carcinoma Treatment Forecast
    • 12.5 Europe Basal Cell Carcinoma Treatment Forecast
    • 12.6 Asia Pacific Basal Cell Carcinoma Treatment Forecast
    • 12.7 Central & South America Basal Cell Carcinoma Treatment Forecast
    • 12.8 Middle East and Africa Basal Cell Carcinoma Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Basal Cell Carcinoma Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Basal cell carcinoma has a low metastasis rate and is more benign, so it is also called basal cell epithelial tumor. Based on its greater destructiveness, it is also called invasive ulcer. Basal cell carcinoma is more common in the elderly, and it occurs in the head, face, neck and back of the hand, especially the prominent part of the face. It begins with a small nodule that is skin-to-dark-infiltrated, typically waxy, translucent nodules with high curled edges. The central part begins to rupture, with black necrotic sputum, and the central necrosis spreads to the deep tissue, showing large invasive necrosis, which can reach soft tissue and bone tissue.
      Among the many treatments, surgical resection is still the most effective treatment for the complete eradication of basal cell carcinoma and avoiding tumor recurrence.
      In addition to surgical resection, other methods that can be used to treat basal cell carcinoma include: radiation therapy, photodynamic therapy, scraping electrocautery, cryotherapy, topical application of drugs, etc.
      The global Basal Cell Carcinoma Treatment market is valued at 4520 million US$ in 2018 and will reach 9090 million US$ by the end of 2025, growing at a CAGR of 9.1% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Basal Cell Carcinoma Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Basal Cell Carcinoma Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Basal Cell Carcinoma Treatment in these regions.
      This research report categorizes the global Basal Cell Carcinoma Treatment market by top players/brands, region, type and end user. This report also studies the global Basal Cell Carcinoma Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Sun Pharmaceuticals
      Valeant Pharmaceuticals International
      Mylan N.V.
      F. Hoffmann-La Roche Ltd
      Merck & Co.

      Market size by Product
      Surgical Excision
      Electrodessication & Cutterage
      Moh's Surgery
      Cryosurgery
      Market size by End User
      Hospitals
      Specialty Clinics
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Basal Cell Carcinoma Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Basal Cell Carcinoma Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Basal Cell Carcinoma Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Basal Cell Carcinoma Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Basal Cell Carcinoma Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Basal Cell Carcinoma Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now